RGRX Stock Chart & Stats
$0.17
$0.00(0.00%)
At close: 4:00 PM EDT
$0.17
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.16 - $0.17
Previous CloseN/A
Volume2.00
Average Volume (3M)205.00
Market Cap
$1.05K
Enterprise Value$1.16M
Total Cash (Recent Filing)$101.56K
Total Debt (Recent Filing)$1.49M
Price to Earnings (P/E)―
Beta276.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,496,966
10 Day Avg. Volume25
30 Day Avg. Volume205
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)-578.70
Price to Sales (P/S)25975.55
P/FCF Ratio-2.12K
Enterprise Value/Market Cap1.10K
Enterprise Value/Revenue15.06
Enterprise Value/Gross Profit15.06
Enterprise Value/Ebitda-3.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RGRX FAQ
What was RegeneRx Biopharmaceuticals’s price range in the past 12 months?
RegeneRx Biopharmaceuticals lowest stock price was $0.16 and its highest was $0.17 in the past 12 months.
What is RegeneRx Biopharmaceuticals’s market cap?
RegeneRx Biopharmaceuticals’s market cap is $1.05K.
When is RegeneRx Biopharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were RegeneRx Biopharmaceuticals’s earnings last quarter?
RegeneRx Biopharmaceuticals released its earnings results on May 15, 2018. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
Is RegeneRx Biopharmaceuticals overvalued?
According to Wall Street analysts RegeneRx Biopharmaceuticals’s price is currently Overvalued.
Does RegeneRx Biopharmaceuticals pay dividends?
RegeneRx Biopharmaceuticals does not currently pay dividends.
What is RegeneRx Biopharmaceuticals’s EPS estimate?
RegeneRx Biopharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RegeneRx Biopharmaceuticals have?
RegeneRx Biopharmaceuticals has 1,496,966 shares outstanding.
What happened to RegeneRx Biopharmaceuticals’s price movement after its last earnings report?
RegeneRx Biopharmaceuticals reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of RegeneRx Biopharmaceuticals?
Currently, no hedge funds are holding shares in RGRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.